Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
- PMID: 31538644
- PMCID: PMC7428393
- DOI: 10.1093/cid/ciz908
Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
Abstract
Background: We assessed the safety and effectiveness of baloxavir marboxil administration in Japanese children with influenza.
Methods: This open-label study administered 1 weight-adjusted dose of baloxavir to 107 children aged 1-11 years with laboratory-confirmed, febrile influenza virus infection of ≤48 hours duration.
Results: Adverse events (AEs) were reported in 34.6% of patients, most commonly vomiting (7.5%); no serious AEs or AEs causing discontinuation occurred. The median time to alleviation of influenza illness was 44.6 hours (95% confidence interval, 38.9-62.5 hours), to resolution of fever was 21.4 hours, and to sustained cessation of infectious viral shedding was 24.0 hours. However, viruses with amino acid substitutions in the viral polymerase acidic protein at position I38 (PA/I38T/M) emerged in 18 of 77 (23.4%) patients. Emergence was associated with longer infectious virus detectability (median time, 180.0 hours) and time to illness alleviation (median, 79.6 vs 42.8 hours in patients without PA/I38T/M-substituted viruses). Among patients with PA/I38T/M-substituted virus emergence, those with baseline hemagglutinin inhibition (HAI) antibody titer <40 experienced delay in time to illness alleviation (median, 85.4 vs 56.0 hours in patients with higher baseline HAI antibody titer).
Conclusions: A single, oral dose of baloxavir marboxil was well tolerated and rapidly reduced viral titers, but the common emergence of PA/I38T/M-substituted viruses warrants consideration of alternative dosing regimens in young children.
Clinical trials registration: Japan Pharmaceutical Information Center Clinical Trials Information (Japic CTI-163417).
Keywords: Japan; antiviral; baloxavir marboxil; children; influenza.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7428393/bin/ciz908f0001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7428393/bin/ciz908f0002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7428393/bin/ciz908f0003.gif)
![Figure 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7428393/bin/ciz908f0004.gif)
![Figure 5.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7428393/bin/ciz908f0005.gif)
Comment in
-
Resistance of Influenza Virus to Antiviral Medications.Clin Infect Dis. 2020 Aug 14;71(4):1092-1094. doi: 10.1093/cid/ciz911. Clin Infect Dis. 2020. PMID: 31538179 No abstract available.
Similar articles
-
Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study.Pediatr Infect Dis J. 2020 Aug;39(8):706-712. doi: 10.1097/INF.0000000000002748. Pediatr Infect Dis J. 2020. PMID: 32433222 Free PMC article. Clinical Trial.
-
Open-label study of the safety, pharmacokinetics, and effectiveness of a 2 mg/kg dose of baloxavir marboxil 2% granules in children <20 kg with influenza.J Infect Chemother. 2021 Aug;27(8):1223-1229. doi: 10.1016/j.jiac.2021.05.009. Epub 2021 May 24. J Infect Chemother. 2021. PMID: 34045119
-
Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.Antiviral Res. 2020 Nov;183:104951. doi: 10.1016/j.antiviral.2020.104951. Epub 2020 Sep 25. Antiviral Res. 2020. PMID: 32987032
-
Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza.Clin Infect Dis. 2020 Oct 23;71(7):1790-1794. doi: 10.1093/cid/ciaa107. Clin Infect Dis. 2020. PMID: 32020174 Review.
-
Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.Drugs. 2020 Jul;80(11):1109-1118. doi: 10.1007/s40265-020-01350-8. Drugs. 2020. PMID: 32601915 Review.
Cited by
-
Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses.Viruses. 2023 Nov 16;15(11):2264. doi: 10.3390/v15112264. Viruses. 2023. PMID: 38005940 Free PMC article.
-
Early Fever Resolution in Early Childhood Influenza Treated with Baloxavir Marboxil: A Retrospective Study Compared to Those with Oseltamivir.Medicina (Kaunas). 2023 Aug 25;59(9):1543. doi: 10.3390/medicina59091543. Medicina (Kaunas). 2023. PMID: 37763660 Free PMC article.
-
Impact of Baloxavir Resistance-Associated Substitutions on Influenza Virus Growth and Drug Susceptibility.J Virol. 2023 Jul 27;97(7):e0015423. doi: 10.1128/jvi.00154-23. Epub 2023 Jul 5. J Virol. 2023. PMID: 37404185 Free PMC article.
-
Accelerating antiviral drug discovery: lessons from COVID-19.Nat Rev Drug Discov. 2023 Jul;22(7):585-603. doi: 10.1038/s41573-023-00692-8. Epub 2023 May 12. Nat Rev Drug Discov. 2023. PMID: 37173515 Free PMC article. Review.
-
Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013/2014-2019/2020 seasons in Japan: an observational study.BMC Infect Dis. 2023 Mar 29;23(1):188. doi: 10.1186/s12879-023-08140-z. BMC Infect Dis. 2023. PMID: 36991360 Free PMC article.
References
-
- World Health Organization. Weekly Epidemiological Record (WER) 23. November 2012; 87: 461–476. Available at: https://www.who.int/wer/2012/wer8747/en/. Accessed 5 April 2019.
-
- Nair H, Brooks WA, Katz M, et al. . Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011; 378:1917–30. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical